Reduction of TMD symptoms
SECONDARY, TSS
The presence of TMD symptoms #1–6 at baseline and after 3 and 6 months of splint treatment are shown in Table Primary and secondary outcomes after occlusal splint treatment.Average TMD symptom score (TSS) at baseline and after 3 and 6 months of occlusal splint therapy. P-values determined by the Friedman test and Conover post hoc test with a Holm–Bonferroni correction (*p < 0.05; **p < 0.0001; ***p < 0.00001).For the purpose of comparing the magnitude of the TSS reduction achieved by AQU- or CPG-based splint therapy, the effect sizes for each symptom were determined at the 3 months- and 6 months follow-up and visualized in a forest plot (Fig. Forest plot for visualizing the effect sizes of the MMR registration method on the reduction of TMD symptoms #1–6 after Aqualizer- or Chin point guidance-based occlusal splint treatment for (